Back to top

Image: Bigstock

Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session

Read MoreHide Full Article

Immunomedics, Inc. (IMMU - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $12.59 to $15.59 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

Immunomedics, Inc. Price

Investors interested in the Medical – Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. (ACOR - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is IMMU going up? Or down? Predict to see what others think:Up or Down

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Immunomedics, Inc. (IMMU) - free report >>

Acorda Therapeutics, Inc. (ACOR) - free report >>

Published in